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Managed Entry Agreements: Lessons from European Payers 
 
AT THE PHARMACCESS LEADERS FORUM ORGANISED BY NEXTLEVEL 
PHARMA IN LONDON IN APRIL 2018, BRIAN GODMAN, SENIOR RESEARCHER AT 
THE STOCKHOLM KAROLINSKA INSTITUTE, PROFESSOR AFFILIATED TO 
SEVERAL UNIVERSITIES AND FORMER MANAGER AT A HEALTHCARE 
CONSULTANCY, PRESENTED AN OVERVIEW OF MANAGED ENTRY 
AGREEMENTS (MEAS) FOR HIGH-COST DRUGS FROM THE VIEWPOINT OF 
EUROPEAN REIMBURSEMENT AGENCIES. AS A PRIVILEGED OBSERVER ± ALSO 
THANKS TO HIS MULTIPLE COLLABORATIONS WITH HEALTH AUTHORITIES ±, 
HE OFFERED VALUABLE INSIGHTS INTO WHAT PHARMACEUTICAL 
COMPANIES CAN DO TO CONCLUDE SUCCESSFUL MEAS. FOLLOWING THE 
MEETING, HE SPOKE TO MARIE-FRANCE COURRIOL OF PPR.  
 
CURRENT CHALLENGES 
Godman presented the position of European payers on managed entry agreements (MEAs) 
VLQFHLQDGGLWLRQWR&DQDGDDQGWKH86³PRVWH[SHULHQFHVRI0($VDUHLQ(XURSH´From 
theVHSD\HUV¶ perspective, the crucial issue today is maintaining free universal healthcare 
access. MEAs offer an option to meet this objective (see PPR January 2014, pp16-19), taking 
into account the multiple challenges that reimbursement agencies must come to terms with: 
³unmet medical needs, rising patient expectations, combined with the need to use financial 
resources as best >WKH\@FDQ´, he advised.   
5HPLQGLQJWKHDXGLHQFHWKDW³KHDOWKFDUHFRVWVUHSUHVHQWDODUJHSRUWLRQRI gross domestic 
product (GDP) (ie 10-15% on average across Europe, with the highest rates in Western 
European countries)´Godman KLJKOLJKWHGWKHIDFWWKDW³SKDUPDFHXWLFDOVDUHDPDMRUEXUGHQ
DQGWKHUHIRUHDµPDMRUIRFXV¶IRUSD\HUVVLQFHWKH\DFFRXQWIRUDEig portion of healthcare 
FRVWV´,QSKDUPDFHXWLFDOVSHQGLQJrepresented 12% of total healthcare expenditure in 
the UK, and 19% in Italy and Spain, for example.  
³That trend will intensify, notably in Europe where QRZ¼ (US$23,600) a month for a 
new treatment is considered cheap. As an increasing number of biological medicines are 
coming through, prices go up, putting real pressure on payers. The focus on medicines will 
also continue because non-communicable diseases DUHRQWKHULVHLQ(XURSH´. This is 
exemplified by VWDWLQVLQ6FRWODQGKHUHPDUNHGZKHUH³Rur volume has jumped fourfold in 
the last 10 years. Other factors putting pressure on the medicines budget are an ageing 
population, and rising obesity rates. So how can we manage that as we go forward?´KH
asked.  
EUROPEAN OVERVIEW 
At the European level, a series of actions are being taken: ³Firstly, health authorities are 
improving in their management of new medicines entry. Previously, health services were 
reactive rather than pro-active with pharmaceutical companies (see PPR June 2012, pp168-
171). Secondly, authorities are getting better at post-launch activities, as shown in Sweden, 
Catalonia, and Scotland ± less so in England. After reimbursement has been granted, they 
check whether expectations have been met in practice´. Godman concludes that this will lead 
to stricter pricing and reimbursement regulations, and to more market access agreements. 
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³1RZadays, only about 10% of new medicines are innovative (data for Austria and France); 
the majority are similar or with a marginal advantage. In the industry, however, every new 
cancer drug is DµFXUH¶, every new µorphan¶ drug LVµDPDJLFEXOOHW¶. The trick now for 
companies is to declare that their new drug is for treating an orphan disease so they can 
charge another US$30,000 a month. That makes payers more cynical when looking at these 
agreements. Payers need to check what the true level of innovation is, whether you call the 
GUXJVµRUSKDQ¶RUQRWfocusing on the substance rather than the hype. When looking for 
LQVWDQFHDWSDWLHQWV¶RYHUDOOVXUYLYDO rates, often new drugs have a limited impact, while we 
DUHSD\LQJ¼HXURVDPRQWKSHUSDWLHQW7KDWLVYHU\GLIILFXOWWRVXVWDLQ´KH
commented.  
 ³8nder value-based pricing, why should we pay more than the current standard by 10 or 20 
times, if the current standard is available as a low-cost generic like imatinib?´*RGPDQ
asked. ³Recent studies have shown that the cost of goods of certain cancer drugs can be as 
low as 1% of the selling price. This was observed in Poland for imatinib following generic 
availability. This knowledge gives payers leverage when negotiating with the industry. Some 
of the new products have an exorbitant price. Take the new Hepatitis C drugs, or cancer drugs 
in the US now averaging US$207,000 per life saved. There is increased prevalence of cancer 
across Europe, and finite budgets. A health authority must be able to get these new drugs 
through which are really innovative and pay for them, but also block or reduce the price of 
those which show little advantage´.  
Godman acknowledged the need of pharmaceutical companies to recoup costs to re-invest, 
³EXWWKHFRVWRI5	'IRUan innovative cancer therapy is probably nearer US$100 million 
rather than the US$1 billion they claim it is.1 Now that Lipitor (atorvastatin) is open to 
generic competition, the price has dropped by 99.5%. Because of this reduction ± a game-
changer ±, payers in Scotland have upped the dose at 40mg for high-ULVNSDWLHQWV´ 
He DGGHG³With my health authority colleagues across Europe, we started thinking about 
new models for the future, based on three pillars:  
x pre-launch: doing horizon scanning to see what the key products are ± particularly 
those addressing unmet needs, or raising concerns with safety or price; building 
registries 
x peri-launch: based on available forecast, having negotiations on pricing and 
reimbursement, and appraising MEAs 
x post-launch: following up, checking registries, quality indicators, and monitoring 
prescribing, etc´.  
*RGPDQHPSKDVL]HGDFULWLFDOSRLQW³LQPRVW(XURSHDQFRXQWULHVIROORZLQJRXWFRPHVXSLQ
patients is very difficult in practice (see PPR August 2017, pp224-227). Germany, Austria, 
France are for example countries with that issue. By contrast, Scotland has some 
comprehensive, interlinked databases. Catalonia has good IT systems, and has been 
successful with the monitoring of gefitinib.  
³The best data is found in Scandinavian countries, as every individual is given a single 
number at birth used for driving licences, as social insurance number, and health number; so 
patients can be tracked well through the system´. In that respect, Godman mentioned his 
collaboration with the Stockholm county council [entity responsible for the day-to-day 
funding and administration of the health system in the Stockholm area (see PPR January 
2017, p150)], which works from µSUH-ELUWK¶of medicines 2 to 3 years before EMA approval 
until disinvestment. The early awareness and alert (EAA) activities ensure that councils plan 
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on the long term, and that the Swedish healthcare system is ready for the introduction of new 
medicines.  
³MEAs are used to facilitate funding and reimbursement through Europe in a situation with 
many uncertainties, where the pharmaceutical industry is wanting to charge a high price for 
new medicines, and payers must work within finite budget limits. Most clinical trials are done 
in perfect patients or as perfectly as possible ± that is, very differently from real life. But we 
know a lot of cancers are not treated as well as they could, and many other diseases are still 
not treated either. How can we put all tKLVWRJHWKHUWRKDYHJRRG0($V"´KHDVNHG 
³Outcome-based and financial-based schemes can be found across Europe, and most will fit 
into the latter category. Financial-based agreements involve for instance payback, rebates, 
price caps or supply of free drugs (see PPR December 2017, p355)´+HQHYHUWKHOHVV
recognised that there can be some overlap between the two types of agreements. 
³*lobally we actually observe a decline in outcome-based schemes, a trend which will 
continue unless we can solve the problem of how to capture patient data as part of routine 
clinical care. The most challenging scheme is found in Italy where every single new 
biological drug has a patient access scheme. This implies maintaining a registry for every 
single cancer or biological medicine, and filling in each single form ± which is a nightmare 
for clinicians (see PPR January 2018, pp10-14). They must do it because hospitals only get 
reimbursed the money for the drug if they fill in the forms. Instead, what you need is just one 
registry you can interrogate: this is being done in Sweden, and in Scotland we can link 
databases together. So, unsurprisingly, most schemes across Europe are price-volume and 
discount-based schemes, just because of the difficulties involved.  
³Most schemes rely on confidential discounts. The National Institute for Health and Care 
Excellence (NICE) has been again recently advocating more discounts via patient access 
schemes. Basically, if NICE gets a discount, it can easily authorise the treatment within four 
weeks through the Patient Access Scheme Liaison Unit (PASLU) (see PPR January 2012, 
pp4-6). For more complicated agreements (eg including dose caps), it would take much 
longer. NICE has entered into 140 patient access arrangements with companies. The Scottish 
Medicine Consortium (SMC) has the same approach, approving 80-90% of medicines, since 
LWFDQJHWVRPHµGHFHQW¶SULFHV through patient access schemes (see PPR October 2017, 
pp298-301). But if they approve 90% of medicines, I would consider NICE and SMC to be 
more of a pricing agency, and no longer a Health and Technology Assessment (HTA) 
agency´. 
Godman then moved on to MEAs in Central and Eastern Europe, judging that they are given 
little exposure compared with Western European countries (see Table 1). ³Poland led the 
process in 2012. Most of the MEAs then were price-volume discount schemes, mostly 
regarding oncology drugs, unsurprisingly due to their high promises´. 5HPDUNDEO\³Uisk-
sharing arrangements have first been put into law by Poland in May 2011, making it the first 
of all European countries to define such agreements legally´.  
PROS AND CONS 
Godman then reviewed the pluses and minuses of financial-based and outcomes-based 
agreements. 
Financial-based Schemes  
³Financial-based schemes enhance the possibility of reimbursement of drugs which otherwise 
would not have been reimbursed, and transfer some of the costs to the pharmaceutical 
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company rather than to the payer. This is essential where concerns of excessive utilisation 
exist. If a manufacturer has a finite price volume agreement, they want to make sure that 
physicians are not overprescribing because that costs them money (see PPR January 2016, 
p22). A company also needs to build in the possibility of dosage creep into any price volume 
agreement. As mentioned for atorvastatin, while the initial dose was 10-20mg, now the 
advocated dose for high risk patients in Scotland is 80mg. The same occurred with 
simvastatin, dosed at 10 and 20mg initially, and now recommended at 40 and 80mg.  
³$QRWKHUFRQFHUQSDUWLFXODUO\ZLWKdose capping scheme, is that of patient confidentiality. 
Issues arose with Lucentis (ranibizumab) around how many injections the patient should 
receive. But ZKRDGPLQLVWHUVWKDW"´ 
³&KDVLQJFRmpanies if the payer wants discounts and rebates can be a headache. Now, 
pharmaceutical companies may help on early access schemes, as they can be complex to 
administer. Having a more IT approach may help with that´.  
As also discussed by Godman, co-payments are an issue ³HVSHFLDOO\in Central/Eastern 
Europe where you have 30 to 70% level co-payments ± less so in Western European 
countries. That is a real disaster for the biological medicines. If a co-payment is based on the 
list price rather than on the discounted price, it is a huge burden for the patient. Looking at 
the management of inflammatory bowel disease in Serbia, we found very little use of the 
biologicals (including anti-tumour necrosis factor [TNF] alpha) because patients just could 
not afford them. This is something to be careful about when hearing claims of µJLYLQJJUHDWHU
DFFHVVWRPHGLFLQHV¶´.  
Outcomes-based Schemes 
,Q*RGPDQ¶VYLHZDQ advantage of such schemes is that patient population can be targeted 
and the agreements can be monitored in practice ± provided there is good patient-level data 
available.  
He nonetheless raised other concerns: ³:hat is the objective of these schemes? Is that fully 
transparent? Who will end up funding the databases and registries? Who pays for putting up a 
new IT system: is that the health authority, is that the pharma company? If there is a paper-
based scheme, like in the Netherlands, do you ask a busy commission to fill in forms, as we 
did in the UK in 2002 with multiple sclerosis drugs [under a risk-sharing scheme whose 
monitoring reportedly cost £1 million/year to the Department of Health and the four drug 
companies that were funding it]? Basically, the government was under pressure to accept 
these new interferons, so they requested the busy neurologists to fill in all these complex 
forms; this really brougKWGRZQWKHQXPEHURISDWLHQWV´ 
*RGPDQDGGHGWRWKDW³WKH OHQJWKRIIROORZXSSDUWLFXODUO\LILW¶VQRWdecided at the outset. In 
fact, multiple schemes were started, where it appeared they were not that beneficial´. When 
an authority decides to extend a scheme when the first set of data is inconclusive, it can last 
an excessive amount of time, at the agreed price rather than at the value price, ³ZKLFKLV± or 
should be ± frightening for payers´. 
Lastly, Godman addressed media pressure (see also PPR January 2014, pp16-19)³/HWPH
take the example of the Netherlands and the enzyme replacement therapy with alglucosidase 
alfa in Pompe disease (see PPR August 2016, pp230-231). FURPDSD\HU¶VSoint view, it was 
known that it did not really work. In 2012, the Dutch Health Care Insurance Board (College 
voor Zorgverzekeringen [CVZ]) passed on a negative decision to the government. The draft 
advice was leaked to the press, as a result triggering all this debate of µKRZPXFKLVDOLIH
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ZRUWK"¶The Dutch government, following pressure from the press, LJQRUHGWKH&9=¶V
advice and funded the medicine, up to ¼15 million per quality-adjusted life year (QALY) for 
the non-classic form of Pompe disease. In a publicly-funded healthcare system, in my 
opinion, this is immoral.2 Of course, nobody wants to be a disinvestment group, everybody 
wants to be an investment group. That is the problem health authorities have: how do they 
disinvest in a product if they find the price is not worth it in practice? This is an issue with so 
many schemes as well´KHQRWHG  
GUIDANCE FOR PHARMA 
Godman believes that 0($V³DUH here to stay and will accelerate. So what pharmaceutical 
companies can do is help to ensure that payers have more accurate data, in order to move 
forward in a solid fashion.  
³Companies could be more transparent RQWKHWUXHFRVWVRIJRRGV´KHDGGHG. ³Payers can 
also look together with companies at alternative funding models, eg transparent value 
framework for orphan diseases; that could be one way of going forward ± talking about the 
levels of uncertainty´. 
One piece of advice for manufacturers willing to enter into talks with health authorities is to 
VWDUWHDUO\³WKUHHyears before the likely European Medicines Agency (EMA) approval (see 
Figure 1); and then to go on with pricing´.  
Furthermore, for companies to get into discussions with payers beyond the question of 
VDYLQJVRQHVXJJHVWLRQIURP*RGPDQLVIRUPDQXIDFWXUHUVWRSURYLGH³PDUNHUVZKLFKFDQ
help agencies identify patients in whom the drug might be particularly effective. When 
reimbursement bodies have a strict budget, and 10 patients they can fund, they want to fund 
all 10 where it is going to work´. He related the example of Velcade (bortezomib) in the UK: 
³NICE rejected it initially (see PPR January 2014, p24), because of its high price, then 
Janssen-Cilag mentioned that they had a scheme which enabled them to target patients for 
whom the treatment would be beneficial. If Janssen-Cilag had proposed that initially, they 
may have obtained a high price.  
³The same happened with $VWUD=HQHFD¶Vlung cancer drug Iressa (gefitinib). Only afterwards 
did the company say that they had a relevant efficiency marker. The issue is that Iressa had 
been launched in Japan in 2002 with a high dose and caused fatal side effects [in over 600 
patients] ± the reason why it was taken off the market. If AstraZeneca had targeted those 
patients for whom the drug could work best, then their drug would probably have remained 
on the market and not be withdrawn to be later re-launched with markers. They might not 
have got as much money as they had expected, but they would have benefitted by remaining 
on the market. And probably in the long run they would have got greater returns´. 
Another winning argument for manufacturers would be to offer to help monitor patients: 
³you can get a reasonable price for that. Generally, if you propose value-based pricing and 
propose to target the patients for an innovative therapy or excellent therapy, then you will be 
very successful. Or should be successfXO´*RGPDQWKHQFRQFOXGHG³3D\HUV want to do more 
worthwhile MEAs because they want more new drugs that work to address continuing unmet 
need´.  
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Table 1: MEAs in Central and Eastern Europe (as of February 2017) 
Country Date of First MEA 
Albania no MEA 
Bosnia and Herzegovina unknown 
Bulgaria 2015 
Croatia 2009 
Czech Republic 2013 
Estonia 2014 
Kosovo no MEA 
Latvia 2013 
Lithuania 2008 
Hungary 2006 
Poland 2012 
Romania 2015 
Russia no MEA 
Serbia 2016 
Slovakia no MEA 
Slovenia 2005 
Note: Other Central and Eastern European countries were either not part of the survey or 
information was unavailable.  
 
Source: Brian Godman, adapted from [3]. 
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Figure 1: Timescale for Implementation of Outcomes-based Schemes 
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3 years prior to EMA approval                                            1 year prior to EMA approval 
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              with main stakeholders  
 
 
Source: Brian Godman, adapted from [2], [4] and [5]. 
 
  
                         
 
 
                                                                            
                                                                   
                                                         
